Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has been recently used as rescue therapy in patients non-responsive to rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts "per se" or requires a priming effect from previous treatments is currently unknown.
Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation
Lavacca, Antonio;Presta, Roberto;Gai, Chiara;Mella, Alberto;Gallo, Ester;Camussi, Giovanni;Abbasciano, Isabella;Barreca, Antonella;Caorsi, Cristiana;Fop, Fabrizio;Messina, Maria;Biancone, Luigi
2020-01-01
Abstract
Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has been recently used as rescue therapy in patients non-responsive to rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts "per se" or requires a priming effect from previous treatments is currently unknown.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Clinical Transplantation - 2020 - Lavacca - Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
1.58 MB
Formato
Adobe PDF
|
1.58 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
